Press inquiries or questions about communications and media:
Director of communications, VCU School of Pharmacy
(804) 828-6470 (office) | (804) 937-4722 (mobile)
School welcomes new faculty
VCU School of Pharmacy is proud to welcome its newest faculty members. From practitioners with long associations with the school to researchers choosing to move to VCU from other states, these recent arrivals continue our pursuit of excellence in health care, research and teaching.
- Apryl N. Anderson, Pharm.D.
Title: Assistant professor in the Department of Pharmacotherapy & Outcomes Science
Most recent job before this one: PGY2 in academic pharmacy, VCU School of Pharmacy
Something most people don’t know about you: I’ve co-piloted a plane (for about five minutes, but still).
- Name: Yana Cen, Ph.D.
- Title: Assistant professor
- Most recent job before this one: Assistant professor at Albany College of Pharmacy and Health Sciences.
- Name: Alexis N. Crawford, Pharm.D.
- Title: Assistant professor
- Most recent job before this one: Critical care clinical pharmacy specialist and PGY1 residency coordinator for Bon Secours Memorial Regional Medical Center.
- Something most people don’t know about you: I have three daughters, am married to a pharmacist, and am allergic to oranges but can tolerate all other citrus (it’s weird!).
- Name: Youssef Roman, Ph.D.
- Title: Assistant professor
- Most recent job before this one: Assistant professor at the Daniel K. Inouye College of Pharmacy, Hilo, Hawaii.
- Something most people don’t know about you: I was born and raised in Egypt so I can speak and write in Arabic.
State approves nation’s first Ph.D. program in pharmaceutical engineering
VCU School of Pharmacy
Virginia Commonwealth University will be home to the nation’s first Ph.D. program in pharmaceutical engineering.
The doctoral program, a collaboration between VCU’s School of Pharmacy and College of Engineering, will focus on research and training students in areas of drug product development such as continuous manufacturing and drug-containing nanomaterials.
VCU received formal notice of the program’s approval by the State Council of Higher Education for Virginia (SCHEV).
“As a nationally prominent research institution, VCU is proud to lead the next wave of pharmaceutical innovation,” said VCU President Michael Rao, Ph.D. “I am grateful to SCHEV for its support of this program and for recognizing how it can benefit the commonwealth and the world.”
The doctoral program will start its first class in the fall of 2020. Its multidisciplinary curriculum will offer students unique professional development opportunities and will cover advanced topics in the field, experimental techniques, and scientific integrity, along with extensive directed and independent cross-disciplinary research.
“Our mission is to provide a student-centric, collaborative and team-based experience for our students. We will prepare the future generation of science and engineering leaders who can act in the pharmaceutical industry as well as in regulatory areas and academic settings,” said Sandro da Rocha, Ph.D., director of the Center for Pharmaceutical Engineering and Sciences in the School of Pharmacy and professor of pharmaceutics. “By training scientists in better delivery systems and new medicines and therapies, we intend to find ways to treat complex diseases, even ones that have been considered untreatable.”
Pharmaceutical engineering and sciences make up key components of the $1.2 trillion pharmaceutical industry. It is a convergent branch of science and engineering that uses a cross-disciplinary approach to design, develop and manufacture pharmaceutical products. Some examples include:
- Applying materials science and engineering to the development of drug delivery carriers and devices
- Applying nanoscience and nanotechnology to medicine
- Developing new technologies for the manufacture of chemicals and biologically active ingredients
- Using computer science and engineering to model processes, harvest and analyze data for the design, discovery and manufacture of active ingredients
- Using engineering and physiology for the development of new devices and formulations
- Designing and manufacturing novel formulations for specific delivery profiles
“The doctoral program in pharmaceutical engineering continues VCU’s advance to a nationally recognized hub for entrepreneurial research and drug delivery, development and manufacturing,” said Thomas D. Roper, Ph.D., the center director in the College of Engineering and a professor of chemical and life-science engineering.
Historically, investment in the development of new medicines has focused on research more than on product delivery and manufacturing. In recent years, however, the United States Food and Drug Administration has encouraged innovations in delivery systems such as nanomedicine and improvements in manufacturing processes to help ensure that patients get the medicines they need safely and effectively.
“The VCU School of Pharmacy has always prepared professionals for the health care needs of the future,” said Joseph T. DiPiro, Pharm.D., dean of the pharmacy school and Archie O. McCalley chair. “This new Ph.D. program supports that mission, and cements VCU’s status as a groundbreaker in health-related education in ways that have visible and powerful effects on our communities.”
Barbara D. Boyan, Ph.D., the Alice T. and William H. Goodwin Jr. dean of the College of Engineering, said, “With the creation of the pharmaceutical engineering Ph.D. program, VCU is seeking to become a national leader in the education of the pharmaceutical workforce of today and innovators leading future developments. The program will address the growing need for a new generation of researchers trained in cross-disciplinary and interdisciplinary science who recognize the need for a team-based approach to solving challenges related to the design and manufacturing of pharmaceutical products.” Learn more about the Center for Pharmaceutical Engineering and Sciences here.
Zhu designs drug delivery systems to test nanovaccines for brain and skin cancer
By Blake Belden
Having a research laboratory on a medical campus, Guizhi Zhu, Ph.D., will often cross paths with cancer patients, and it’s during those instances that he is most driven to continue his work.
“I sometimes feel helpless because I can’t do much for them in that moment other than saying some kind words,” he said. “Those are the moments that help me focus on my research to potentially have an impact that can change or improve therapeutic outcomes for cancer patients.”
Guizhi “Julian” Zhu uses innovative drug delivery platforms to test the efficacy of novel immunotherapeutics for a variety of disease types including skin, liver, brain, colorectal and breast cancers.
He joined VCU Massey Cancer Center as an associate member of the Developmental Therapeutics research program in 2018, and he is an assistant professor in the Department of Pharmaceutics and Center for Pharmaceutical Engineering and Sciences at the VCU School of Pharmacy.
Leveraging an extensive background in engineering, chemistry and pharmacology, Zhu designs targeted drug delivery systems and develops cancer nanomedicines such as nucleic acid nanovaccines for enhanced therapeutic benefit. Nanovaccines are vaccines that dispense microscopic particles into the immune system to stimulate a response against cancer cells, and they hold promise for treating disease more effectively than existing vaccines. Zhu tests a variety of nucleic acids, including immunomodulatory DNA/RNA, gene-expression modulation DNA/RNA, drug-encoding mRNA or gene-editing nucleic acids.
Zhu currently holds several grants to support studies on nanovaccines for glioma, a tumor of the brain and spinal cord, and melanoma, the deadliest form of skin cancer.
Under the mentorship of Steven Grossman, M.D., Ph.D., deputy director of Massey, Zhu holds an American Cancer Society Institutional Research Grant (ACS-IRG) to study the combination of an immunotherapy and an immuno-activating chemotherapy to treat melanoma.
He is also one of the principal investigators , together with Kristoffer Valerie, Ph.D., and Paula Bos, Ph.D., members of the Cancer Molecular Genetics research program at Massey, on a Massey Pilot Project that will explore the combination of a nanovaccine, immune re-energizing drugs and radiation therapy to treat glioma in mouse models.
“This project is really exciting because there isn’t a durably effective treatment option for glioma,” Zhu said. “We hope that by using radiation we can jump start the tumor microenvironment to make immunotherapy more effective.”
He is a KL2 Mentored Clinical Research Scholar under the mentorship of Douglas Sweet, Ph.D., and Sandro da Rocha, Ph.D., an Endowment Fund awardee from the VCU Wright Center for Clinical and Translational Research and a VCU Presidential Research Quest Fund recipient.
Zhu leads a research team of six postdocs and graduate students as well as multiple undergraduate students and visiting scholars.
He grew up in China where he earned a bachelor’s degree in biotechnology from Nankai University. Zhu moved to the United States, where he earned his Ph.D. in medical science – physiology and pharmacology – and also completed a postdoctoral fellowship in cancer nanomedicine at the University of Florida. He finished a second postdoctoral fellowship in cancer immunotherapy and bioimaging from the National Institute of Biomedical Imaging and Bioengineering in Maryland. During this time, Zhu collaborated in famous and well-established laboratories to engineer and image nanomedicines. It was following this fellowship when he centered his work around cancer immunotherapies.
“Because the nature of my work is heavily focused on cancer immunotherapy, the scientific combination of pharmaceutics and cancer offers an ideal environment for me at Massey,” Zhu said.
Zhu has published more than 70 articles in peer-reviewed journals, including Nature Communications, Proceedings of the National Academy of Sciences, Journal of the American Chemical Society, ACS Nano, Angewandte Chemie, among others. His publications have been cited by peers more than 4,500 times in the past five years, according to Google Scholar. Zhu is a member of the American Chemical Society, the Oligonucleotide Therapeutics Society and the Society for Immunotherapy of Cancer. He received a Distinguished Scientist Award from the National Institutes of Health in 2017, and he was awarded the Alan M. Gewirtz Memorial Fellowship by the Oligonucleotide Therapeutics Society (2013), among other awards.
Zhu lives with his daughter and mother in Richmond, and they await the arrival of his wife who is close to finishing her doctoral degree in food science and nutrition in Maryland.
Living with little-known disorder Ehlers-Danlos sparked Miss Virginia’s love of science
By Emiley Bagalawis
VCU School of Pharmacy News
Camille Schrier won the title of Miss Virginia in June with the help of her science-related talent exhibition — a demonstration of the catalytic conversion of hydrogen peroxide that created a dramatic burst of colored foam on the pageant stage.
That win and the video of her demonstration led millions to see her story on TV news reports, social media and websites. She has been hailed for breaking stereotypes and as a role model for young women.
But most people have no idea of the disorder that helped inspire her career in science.
Camille is living with Ehlers-Danlos Syndrome, a genetic condition that affects body tissue, joints and blood vessels. She was diagnosed when she was 11.
“It definitely got me interested in science and medicine because there’s no treatment for this right now,” Camille says. “There was a lot of genetic information regarding EDS and genetics was something I was always really interested in. This was a further interest, in terms of genetics, for me to look at and think about how that could help us diagnose people.”
Camille’s family noticed something was wrong as soon as she was born: Camille was born with her hips dislocated. She also fell a lot as a child and was prone to injuries because EDS can make people less stable. She found out she had EDS when she went to see an orthopedic surgeon for scoliosis, which her family learned was caused by her EDS.
She lives with pain from the condition. Her level of pain varies in intensity from day to day, sometimes making her feel like she has the flu.
“It’s not like shooting, burning or electric pain. It’s kind of a dull chronic achiness that I get frequently,” she says. “It … rarely interferes with my everyday life. But it’s definitely a reminder that it’s there.”
EDS affects about 1 in 5,000 people. There are 13 different types, classified based on the symptoms and signs that patients show. Common symptoms include loose and unstable joints that can lead to frequent dislocations, joint pain, fragile skin that can bruise easily, and poor wound healing. EDS can cause early onset osteoarthritis, scoliosis, musculoskeletal pain, arterial/intestinal/uterine fragility or rupture, poor muscle tone and gum disease.
Camille has classic EDS, which affects the genes in her type V collagen. Symptoms include joint hypermobility, skin hyperextensibility and skin fragility that leads to scarring and bruising.
It is a genetic condition. Camille and her mother, Cheryl Schrier, were both diagnosed at the same time. Cheryl Schrier says she would get injured frequently as a teenager but was consistently blown off as being “overdramatic.”
“Camille was experiencing some of the same [experiences I had],” Cheryl says. “Her swim coach told her she was ‘trying to get out of the hard work’ when her shoulder dislocated repeatedly during backstroke practices, and field hockey coaches told her to ‘walk off’ ankle subluxations and hand injuries.”
The Schriers’ experience rings true for Tahnee N. Causey, a genetic counselor and assistant director of the VCU Genetic Counseling Program who has worked with many patients with EDS.
Friends, co-workers and even physicians often do not understand a disorder like EDS that has few visible signs but that can cause real injury and pain, Causey says. Common symptoms of EDS include migraine, joint pain, gastrointestinal distress, poor wound healing and postural orthostatic tachycardia syndrome, or POTS, a circulatory condition in which people become lightheaded and dizzy when they stand up.
It is not unusual for EDS patients to struggle for a long time to convince doctors that their symptoms are real, Causey adds: “For some of our patients it’s a real validation that they have a diagnosis.”
Causey, who says her office evaluates about 10 patients a week who show signs that may mean they have the disorder, suspects it is more common than even many experts think.
Starting in September 2019, VCU Health is beginning a twice-monthly clinic with practitioners from different medical disciplines to help treat patients with EDS.
Camille Schrier says she hopes that speaking about her condition helps people, particularly healthcare professionals and pharmacy students, understand that EDS is “wildly misdiagnosed” and more common than people realize since there are many different strains of the disorder.
“I have something that causes me pain constantly and causes me injury and chronic fatigue sometimes,” she says. “That’s something I deal with, and there are many other people that have illnesses that are not obvious.”
Camille has taken a one-year leave of absence from her Pharm.D. studies. She is currently travelling the state, sharing her STEM platform as Miss Virginia. She will compete in the Miss America pageant in September.
To learn more about Ehlers-Danlos Syndrome visit https://www.ehlers-danlos.com.
Note: This article was edited on Aug. 8, 2019, to add information from an interview with Tahnee Causey.
VCU team explores epigenetics as cause of adverse drug reactions in elderly
Director of Communications
VCU School of Pharmacy
A VCU School of Pharmacy research team is studying how aging affects the ways drugs interact with the body. The results may help doctors better manage medications in older patients.
The aim is to better understand why older people seem to metabolize drugs more slowly, with the goal of someday seeing fewer adverse drug reactions and hospitalizations among the elderly, said the principal investigator, Joseph McClay, Ph.D., an assistant professor in the VCU School of Pharmacy’s Department of Pharmacotherapy and Outcomes Science.
Older patients are almost seven times as likely to be hospitalized for adverse drug reactions than younger ones, according to a 2006 study in the Journal of the American Medical Association. A separate study in the United Kingdom found that adverse drug reactions contributed to 6.5% of hospital admissions and primarily occurred in older patients.
The causes for these disparities are not well known, McClay said.
The study, supported by a $454,000 grant from the National Institute on Aging, will explore how genetic factors that are turned on and off by the body — a process known as epigenetics — affect how the body interacts with medications as it ages.
The body’s genes, its DNA, do not change over time. But its epigenetics, how the body expresses those genes, does. The VCU team will begin the process of tracking how these epigenetic changes affect the body’s reaction to drugs.
McClay and his colleagues — Elvin Price, Pharm.D./Ph.D., and Matthew Halquist, Ph.D., in the VCU School of Pharmacy and Mikhail Dozmorov, Ph.D., and Patrick Beardsley, Ph.D., in the VCU School of Medicine — and a team of graduate students will begin by mapping age-related changes in key genes using samples of livers from aged mice from the National Institute on Aging.
This map of epigenetic changes, McClay said, will help researchers understand how the liver, the body’s main organ for metabolizing drugs and other outside chemicals, could interact with medicines in older bodies.
Once the mapping is complete, the team plans to focus on a gene known as CYP2E1, which is part of the liver’s system of metabolizing chemicals such as drugs and alcohol and has been shown by the VCU team and others to be expressed differently in older bodies.
In particular, the VCU researchers will study how chlorzoxazone, a drug metabolized by CYP2E1, is affected. If livers from older mice metabolize the drug more slowly, as McClay and his team predict, this could lead to greater understanding of the reasons that older humans are affected differently by medications. and iIn time this could lead to better medication dosing in elderly patients.
“That is the point, in the end,” McClay said. “We want to keep people healthy.”
Price named Yanchick professor and director of geriatric pharmacotherapy
Elvin T. Price, Pharm.D./Ph.D., has been named Victor A. Yanchick professor and director of the Geriatric Pharmacotherapy Program at VCU School of Pharmacy. He takes over the roles from longtime professor Patricia Slattum, who retired earlier this year.
The Yanchick professorship is named for Victor A. Yanchick, dean of the School of Pharmacy from 1996 to 2014, and has the goal of providing sustained leadership for the geriatrics program.
“We are thrilled that Dr. Price has agreed to take on this role and lead the Geriatric Pharmacotherapy Program,” said Joseph T. DiPiro, Archie O. McCalley chair and dean of the School of Pharmacy. “His experience and dedication to improving health among older patients will guide the program into the future of geriatric medicine.”
Price joined VCU School of Pharmacy in 2017 from University of Arkansas for Medical Sciences in the College of Pharmacy, where he was an assistant professor, as an associate professor in the Department of Pharmacotherapy and Outcomes Science. He also is affiliated with VCU’s Institute for Inclusion, Inquiry and Innovation (iCubed), focusing on health and wellness in aging populations.
“Older adults have a special place in my heart,” Price said. “As a child I witnessed several of my older relatives live with, and die from, diabetes and heart diseases. This suffering inspired me to pursue a career studying the impact of genetic variation on aging and how people respond to medications.”
Price earned his doctorate in pharmacy from Florida Agricultural and Mechanical University and his Ph.D. in clinical pharmaceutical sciences and pharmacogenomics from the University of Florida. His published research has focused largely on pharmacogenomics and personalized medicine, as well as on health issues such as diabetes and substance abuse.
‘I’m trying to be like Bill Nye’: How Camille Schrier’s interest in science helped her become Miss Virginia
By Emiley Bagalawis
School of Pharmacy News
Camille Schrier’s science and medical education led her to stop taking part in pageants. That same education helped her become Miss Virginia 2019.
Schrier, 23, a doctor of pharmacy student at Virginia Commonwealth University, was awarded the statewide title in Lynchburg on June 22. She was one of 24 contestants. As Miss Virginia, she will represent the commonwealth in the Miss America competition.
Instead of dance or baton twirling, Schrier’s winning talent presentation featured her in a white lab coat and safety goggles mixing chemicals to create spouts of colorful foam that shot far above the stage.
A few days after her win, Schrier stopped by VCU.
“It’s been crazy,” she said. “It’s been a wild ride.” She recalled being escorted from the competition after her win by guards who ushered her into a waiting car. “I felt like the president,” she added with a laugh.
Schrier is in the process of moving into a Roanoke apartment provided to her as part of her reign. She will take a year off from her studies at VCU to tour the state and share her campaign platform of STEM awareness and drug safety.
“I’m trying to be like Bill Nye [the science guy],” she said. “That’s what I’m going for. I want to get kids excited, but I don’t want it to be boring.”
Schrier, a Pennsylvania native, said she was an athletic kid, never a “girly-girl.” She attributes her love of science and nature to an eighth-grade science class. When she was 14, she became interested in pageants as a creative outlet.
The process taught her more than she expected, she said: “It taught me a lot about being professional … in terms of just being able to prepare a resume, go into an interview confidently, and how to prepare for something like that.”
Schrier participated in pageants from age 14 until she started college four years later. She graduated cum laude from Virginia Tech in 2018 with degrees in biochemistry and systems biology. She entered VCU’s Doctor of Pharmacy program last year.
Lauren Caldas, Pharm.D., an assistant professor in the School of Pharmacy, taught Schrier in a challenging first-year pharmacy foundations course.
“In a class where a lot of students can become very stressed, she shined and was just a wonderful person to be around. She was always an example of professionalism,” Caldas said.
Around the time Schrier started pharmacy school, she learned that the Miss America pageant had been revamped — eliminating the swimsuit competition and emphasizing professionalism and social impact. That, and the possibility of scholarships, reignited her interest. The Miss America organization says it is the nation’s top provider of scholarships for young women.
Building on her pharmacy education, Schrier decided she would make her platform “Mind Your Meds,” focusing on drug safety and abuse prevention. Since Schrier did not have much experience in performing, she realized she would have to find a way to highlight her talents that was entertaining on stage.
After looking online for science experiments for kids, she came across an experiment sometimes called “elephant toothpaste” that demonstrates the rapid decomposition of hydrogen peroxide using potassium iodide as a catalyst. The result is a dramatic burst of foam.
She acquired some industrial-strength hydrogen peroxide and practiced the experiment in the driveway of her apartment complex, adding food coloring to the foam. When she tried it in an outdoor car wash, the foam shot out so violently it hit the ceiling, staining it. (She scrubbed it clean with bleach.)
Her science experiment helped her win a regional title, Miss Dominion, making her eligible for the Miss Virginia pageant. Because the Miss Virginia competition would be held in a large space, she made her experiment bigger, with larger flasks and even more dramatic jets of brightly colored foam. She won the preliminary talent award.
“I expected to hear some feedback saying that my talent wasn’t really a talent,” Schrier said. “But I will tell you, I was overwhelmed with messages saying how cool my talent was, how refreshing it was and how everyone was impressed that I was able to tie education and science into something that was also entertaining.”
David Holdford, Ph.D., a professor in the Department of Pharmacotherapy and Outcomes Science in the VCU School of Pharmacy, worked with Schrier on her research fellowship.
“After finding out she was competing for Miss Virginia, I was really happy for her,” Holdford said. “To me, it seemed her focus on medication safety and science were very innovative and would give her a chance to win.”
After her year as Miss Virginia, Schrier plans to return to VCU to complete her pharmacy degree. She had applied to three pharmacy schools but said VCU “blew every other school out of the water.”
“It’s a community of people that help each other and that’s something that immediately drew me to want to be a student here,” she said.
Schrier is not the only VCU pharmacy student to participate in the Miss Virginia competition. Taylor Reynolds, Miss Arlington, is a rising third-year Pharm.D. student and was one of the top 12 contestants who competed with Schrier on June 22. Last year Reynolds was second runner-up, winning $4,000 in scholarships.
In 2007, then-School of Pharmacy student Traci Poole, now founder and CEO of Apothecary pharmacy in Nashville, was second runner-up in the pageant. “I’ll forever be grateful for the years of experience in pageantry with the Miss VA USA system as it honed so many essential skills such as public speaking, networking, advocating for something I’m passionate about, and thinking critically on my feet,” Poole wrote in an email. “All of which have enabled success for my career no matter the opportunity that arises!”
Schrier said her education in the sciences has not always been easy.
“I didn’t have that kind of role model who had gone through the same experiences that I had of being an undergrad in a science career,” she said. “And now I’m in a graduate program. It’s not easy [getting a science degree] and I want to be that person to go out there and encourage and show them that I did it. And so can you.”
Watch her winning science experiment on stage at the Miss Virginia pageant in this home video:
Watch #VCUPharmacy student Camille Schrier wow the judges for Miss Virginia with her talent performance — the catalytic decomposition of hydrogen peroxide!
— VCU School of Pharmacy (@VCUPharmacy) June 26, 2019
Introducing our Heritage Trail video series on pharmacy history
As part of the school’s Heritage Trail project documenting the history of pharmacy in Virginia and across the world, we have worked with Ost Haus, a creative agency and video production company in Richmond, and alumnus Al Schalow (B.S./Pharm ’61) to present a series of short videos.
Each of the four videos summarizes an aspect of pharmacy history. They are narrated by Schalow and feature illustrations created originally for National Geographic.
We are proud to share these educational videos. They’re a perfect way to introduce people to the profession’s long and illustrious history, and would be ideal for young students.
(Above) Part 1: Potions and Poisons
In part 1, Schalow travels to prehistoric times and ancient lands to explore the ways plant medicines and other remedies were discovered and refined.
Part 2: Ancient Pharmacy
In this video Schalow discusses ancient civilizations around the world that discovered and refined medications that still are familiar in pharmacy today.
Part 3: Frauds vs. Folk Wisdom
Schalow examines the wild days of U.S. pharmacy that brought us patent medicines and dangerous quacks — and how the nation responded.
Part 4: Helpful and Hazardous
In “Helpful and Hazardous,” Schalow focuses on the double-edged sword of drugs that can save and enrich lives — and also endanger individuals and society.
High school students get a closer look at pharmacy as a career
VCU School of Pharmacy News
On the tables of a gray classroom sit red buckets with hazard signs, latex gloves, cotton balls and black zippered bags. Twelve students, all teenagers, are seated at the tables. The scent of alcohol rises from opened packets as they nervously wipe their fingertips, trying to be brave.
One student takes out a meter from the black bag and inserts a small test strip. Her hand shakes as she aligns a needle with her finger, but she can not go through with it. She asks the instructor to do it for her.
“OK,” says instructor Mason Bader, a third-year pharmacy student. “On three. One —” A small snap rings out. The girl flinches, then sighs in relief. She massages her finger until a small drop of blood appears.
The students are taking part in the first year of the Pharmacy Summer Scholars program for high schoolers who are interested in a career in pharmacy. The program ran from June 17 to 21.
Most of the students are from the Richmond region; one is from California. Jasia Redmond is a rising junior from Hanover High School and heard about Pharmacy Summer Scholars through her school’s pharmacy program called The Specialty Center.
“I decided to do this because I was interested to learn more about pharmacy,” Redmond says. “It seemed interesting.”
The program is a part of VCU Pipeline Programs. Participants are charged $50 to cover food and materials, with waivers available. These programs aim to educate students on different health-science careers and diversify the health-care workforce and are offered to middle, high and college students. Middle schoolers can participate in a program offered called Pharmacy Explorers that is similar to the Pharmacy Summer Scholars.
Taryn Hayes, assistant director of recruitment and pipeline programs at VCU School of Pharmacy, is in charge of the Pharmacy Scholars program.
“I want students to have an understanding of pharmacy and the other career pathways that you can go into with a degree in pharmacy,” Hayes says. “I also want them to know about social determinants of health and why culture is important when administering care. Like how you create treatment plans based on a person’s culture. I want them to understand what culture is and how that impacts the way they treat patients.”
The five-day program features activities, discussion and lessons. Jordan Gray is a rising junior. He says one of his favorite parts of the program has been tic-tac-toe. The students play a variation of the classic game to test what they have learned so far. “It was fun,” Gray says, “it was very competitive and it opened us up to each other.”
The program also offers plenty of hands-on activities. On a recent day, in addition to a lecture about blood pressure, blood glucose
and body mass index, third-year pharmacy students Mason Bader and Nick Suarez show students how to take blood pressure and test glucose levels — the purpose of that scary needle prick.
“We take blood to measure glucose because glucose likes to stick to our red blood cells,” Bader says. “Glucose levels are measured in millimeters of glucose per liter of blood.”
Pharmacists are trained to take vital signs such as heart rate, breathing rate and body mass index in addition to blood pressure and glucose levels, the instructors explain. Suarez demonstrates how to take someone’s blood pressure using a blood pressure cuff and a stethoscope.
“After pumping up the cuff, you deflate it slowly while watching the needle fall back down,” Saurez says. “You listen for the first ‘glug,’ which is the blood rushing back in your arm, and keep a note of what number the needle passes when doing so. Then you listen for the last ‘glug’ and see what number the needle passes.”
He takes Bader’s blood pressure. The first glug is at 172, Suarez announces, the last at 72. “So his blood pressure is 117 over 72, which is normal,” Suarez says.
Another hands-on activity is led by Wylie Crane, a fourth-year pharmacy student. She gives a short lecture on compounding. Compounding is when pharmacists prepare medicines by combining or mixing ingredients.
“I call it pharmacy cooking because you take the ingredients from scratch and you make something new,” Crane says.
To get experience in compounding, the students head into a lab where they work in pairs to make lip balm—think ChapStick—out of coconut oil, cocoa butter, beeswax and a flavoring. A glass beaker is placed in a water bath to heat the ingredients after they are carefully measured. After the ingredients are melted and mixed together, the students pour the solution into molds to cool.
It’s the same process a doctor in Lynchburg, Virginia, used to invent ChapStick almost 150 years ago, and basically the same process taking place by the millions less than 20 miles away at the country’s only ChapStick factory.
The students take part in other activities such as creating a suspension of medication particles in liquid that can be taken by mouth or rubbed on skin.
And, of course, blood tests for glucose.
“Your glucose level is 105,” instructor Bader tells the student who was so anxious about pricking her finger. “Which is normal.”
The student wraps her injury with a Band-Aid. She looks pleased.
Robb named 2019 Congressional Healthcare Policy Fellow
May 22, 2019
For immediate release
Contact: Kristen Zimmerman, (804) 628-5074
Kyle G. Robb has been named the American College of Clinical Pharmacy-American Society of Health-System Pharmacists-Virginia Commonwealth University Congressional Healthcare Policy Fellow for 2019-20.
Pharmacists selected for the position have the opportunity to gain real-world insight into health care policy analysis and development via immersion in the congressional environment. Fellows are actively mentored in legislative evaluation, policy development, research and writing while integrating practical experience with theory.
Robb currently works as a pharmacy supervisor with the University of Virginia Health System. He holds a Pharm.D. from the Eshelman School of Pharmacy at the University of North Carolina and bachelor’s degrees in history and chemistry from North Carolina State University.
He credits his work at U.Va.’s hospital with his interest in public policy. That experience “put me into contact with many patients with needs that far outweighed their personal resources,” he said.
“There are still many barriers to care facing large portions of the general population and each problem requires an individualized solution,” Robb added. “I’ve seen how barriers in perception can prevent people from seeking care that they did not realize they had access to. I’ve seen well-meaning policies implemented in manners that do not best serve all patients and I have been tasked with finding ways to help the excluded patients. … There are many problems still in need of solutions that collectively represent massive opportunity to better manage healthcare resources and thereby improve people’s lives.”
After completing the fellowship Robb plans to work in health policy as part of government or through academic research.
The Congressional Healthcare Policy Fellow program will begin in July. Robb will spend one week at the Brookings Institution and three weeks each with ACCP’s and ASHP’s government affairs offices. Finally, he will embark on his placement within a congressional office or on congressional committee staff in Washington, D.C.
The fellowship program, now directed by VCU School of Pharmacy associate professor Kristin Zimmerman, was founded 12 years ago under the leadership of professor Gary R. Matzke.
For more about the ACCP-ASHP-VCU Congressional Healthcare Policy Fellow program, click here or contact director Kristin Zimmerman at email@example.com.